ATE517879T1 - 4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7- ylverbindungen zum modulieren der b2- adrenorezeptoraktivität - Google Patents

4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7- ylverbindungen zum modulieren der b2- adrenorezeptoraktivität

Info

Publication number
ATE517879T1
ATE517879T1 AT07848598T AT07848598T ATE517879T1 AT E517879 T1 ATE517879 T1 AT E517879T1 AT 07848598 T AT07848598 T AT 07848598T AT 07848598 T AT07848598 T AT 07848598T AT E517879 T1 ATE517879 T1 AT E517879T1
Authority
AT
Austria
Prior art keywords
benzothiazole
dihydro
oxo
modulating
hydroxy
Prior art date
Application number
AT07848598T
Other languages
English (en)
Inventor
Stephen Connolly
Alexander Humphries
Premji Meghani
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE517879T1 publication Critical patent/ATE517879T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT07848598T 2006-12-20 2007-12-19 4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7- ylverbindungen zum modulieren der b2- adrenorezeptoraktivität ATE517879T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87092206P 2006-12-20 2006-12-20
US91004507P 2007-04-04 2007-04-04
US95198007P 2007-07-26 2007-07-26
PCT/GB2007/004861 WO2008075026A1 (en) 2006-12-20 2007-12-19 4-hydr0xy-2-0x0-2, 3 -dihydro- 1, 3-benzothiazol- 7yl compounds for modulation of b2-adrenoreceptor activity

Publications (1)

Publication Number Publication Date
ATE517879T1 true ATE517879T1 (de) 2011-08-15

Family

ID=39167020

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07848598T ATE517879T1 (de) 2006-12-20 2007-12-19 4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7- ylverbindungen zum modulieren der b2- adrenorezeptoraktivität

Country Status (20)

Country Link
US (3) US7700782B2 (de)
EP (1) EP2121642B1 (de)
JP (1) JP2010513440A (de)
KR (1) KR20090091342A (de)
AR (1) AR064635A1 (de)
AT (1) ATE517879T1 (de)
AU (1) AU2007336075B2 (de)
BR (1) BRPI0722096A2 (de)
CA (1) CA2672811A1 (de)
CL (1) CL2007003765A1 (de)
CO (1) CO6190554A2 (de)
EC (1) ECSP099426A (de)
IL (1) IL199014A0 (de)
MX (1) MX2009006009A (de)
NO (1) NO20092691L (de)
PE (1) PE20081544A1 (de)
SA (1) SA07280728B1 (de)
TW (1) TW200833670A (de)
UY (1) UY30808A1 (de)
WO (1) WO2008075026A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200745067A (en) * 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
WO2009138707A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
AU2009247021B2 (en) * 2008-05-13 2012-06-07 Astrazeneca Ab Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist
UY31905A (es) 2008-06-18 2010-01-29 Astrazeneca Ab Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
MX2010013416A (es) * 2008-06-20 2010-12-21 Astrazeneca Ab Composicion farmaceutica que comprende un compuesto de 4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-ilo para la modulacion de la actividad del adrenorreceptor beta 2.
GB0814728D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
EP3052190A4 (de) * 2013-10-01 2017-07-19 New York University Amino-, amido- und heterocyclische verbindungen als modulatoren der wutaktivität und verwendungen davon

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2653977A (en) * 1953-09-29 Chxnx
US3775477A (en) * 1971-03-10 1973-11-27 Sterling Drug Inc N,n'-bis(2-aryl-2-(hydroxy or oxo)-ethyl)-bridged-bis-carboxamides
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
AU581887B2 (en) 1984-04-17 1989-03-09 Glaxo Group Limited Ethanolamine compounds
US4554284A (en) 1984-09-12 1985-11-19 Smithkline Beckman Corporation 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones
US4554287A (en) 1984-09-12 1985-11-19 Smithkline Beckman Corporation Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones
GB8525483D0 (en) 1985-10-16 1985-11-20 Glaxo Group Ltd Chemical compounds
GB8718938D0 (en) 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
NZ235605A (en) 1989-10-10 1992-12-23 Glaxo Group Ltd (r)-(-)-4-hydroxy-alpha 1 -(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol and pharmaceutical compositions
GB9211172D0 (en) 1992-05-27 1992-07-08 Fisons Plc Compounds
US5648370A (en) * 1990-11-20 1997-07-15 Astra Pharmaceuticals Limited 7-(2-aminoethyl) benzothiazolones
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
GB9210632D0 (en) 1992-05-19 1992-07-01 Fisons Plc Compounds
TW356468B (en) * 1995-09-15 1999-04-21 Astra Pharma Prod Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same
GB9526511D0 (en) 1995-12-23 1996-02-28 Astra Pharma Prod Pharmaceutically active compounds
WO1997044329A1 (en) 1996-05-20 1997-11-27 Teijin Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
SE9700706D0 (sv) 1997-02-27 1997-02-27 Astra Pharma Prod Process for the preparation of benzothiazoline compounds
SE9701304D0 (sv) 1997-04-09 1997-04-09 Astra Pharma Prod Compounds
JP2002509119A (ja) 1998-01-13 2002-03-26 アストラゼネカ ユーケイ リミテッド ドーパミン（Ｄ２）レセプターアゴニスト活性を有する化合物およびβ２−アドレナリンレセプターアゴニスト活性を有する化合物（Ｂ）を含有する薬学的組成物
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6683115B2 (en) * 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
SE9902935D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902936D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902937D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902938D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
RU2312854C2 (ru) 2001-09-14 2007-12-20 Глаксо Груп Лимитед Производные фенэтаноламина для лечения респираторных заболеваний
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) * 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
JP2005187357A (ja) 2003-12-25 2005-07-14 Nippon Suisan Kaisha Ltd 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1577306A1 (de) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
WO2005092841A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
WO2005110990A1 (de) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7402673B2 (en) 2004-06-03 2008-07-22 Theravance, Inc. Diamine β2 adrenergic receptor agonists
US7317023B2 (en) 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
EP1778626A1 (de) 2004-08-16 2007-05-02 Theravance, Inc. Zusammensetzungen mit beta2-adrenergen-rezeptoragonist- und muskarinrezeptorantagonist-aktivität
EP1833822A2 (de) 2004-08-16 2007-09-19 Theravance, Inc. Verbindungen mit beta2 adrenerg-rezeptor agonistischer und muscarin-rezeptor antagonistischer aktivität
WO2006031556A2 (en) 2004-09-10 2006-03-23 Theravance. Inc. Amidine substituted aryl aniline compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
CN101137625A (zh) 2005-01-11 2008-03-05 葛兰素集团有限公司 β2肾上腺素能激动剂的肉桂酸盐
GB0511066D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
RU2008101897A (ru) 2005-07-18 2009-07-27 Пфайзер Лимитед (GB) Способ получения сульфонамидных производных
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200740781A (en) 2005-08-29 2007-11-01 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
US20090029958A1 (en) * 2006-03-08 2009-01-29 Lilian Alcaraz Phenethanolamine derivatives as beta2 adrenoreceptor agonists
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
WO2008041914A1 (en) 2006-10-06 2008-04-10 Astrazeneca Ab 5-(2-AMINO-L-HYDROXYETHYL)-8-HYDROXY-2-OXOQUINOLINE DERIVATIVES AND OTHER COMPOUNDS AS β2 -ADRENERGIC AGONISTS
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
BRPI0722095A2 (pt) 2006-12-20 2014-04-01 Astrazeneca Ab Derivados de amina e seu uso em doenças mediadas por beta-2-adrenor-receptor
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0702459D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 669
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
GB0703999D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
WO2009037503A2 (en) 2007-09-18 2009-03-26 Astrazeneca Ab New combination - 012 for the treatment of respiratory diseases
MX2010006657A (es) * 2007-12-20 2010-10-05 Astrazeneca Ab Dispositivo y metodo para desagregar polvo 854.
MX2010013416A (es) * 2008-06-20 2010-12-21 Astrazeneca Ab Composicion farmaceutica que comprende un compuesto de 4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-ilo para la modulacion de la actividad del adrenorreceptor beta 2.

Also Published As

Publication number Publication date
PE20081544A1 (es) 2009-01-11
HK1136572A1 (en) 2010-07-02
KR20090091342A (ko) 2009-08-27
EP2121642B1 (de) 2011-07-27
UY30808A1 (es) 2008-07-31
CL2007003765A1 (es) 2008-08-22
US7700782B2 (en) 2010-04-20
NO20092691L (no) 2009-09-16
US20100022491A1 (en) 2010-01-28
SA07280728B1 (ar) 2010-12-01
AR064635A1 (es) 2009-04-15
ECSP099426A (es) 2009-07-31
BRPI0722096A2 (pt) 2014-04-01
CA2672811A1 (en) 2008-06-26
CO6190554A2 (es) 2010-08-19
TW200833670A (en) 2008-08-16
AU2007336075B2 (en) 2011-10-27
EP2121642A1 (de) 2009-11-25
IL199014A0 (en) 2010-02-17
MX2009006009A (es) 2009-06-16
US20080207698A1 (en) 2008-08-28
JP2010513440A (ja) 2010-04-30
WO2008075026A1 (en) 2008-06-26
US20100249200A1 (en) 2010-09-30
AU2007336075A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
ATE517879T1 (de) 4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7- ylverbindungen zum modulieren der b2- adrenorezeptoraktivität
DK2035396T3 (da) Triazolforbindelser der modulerer hsp90-aktivitet
BRPI0917634A2 (pt) benzoxazolas, benztiazolas e análogos relacionados como moduladores de sirtuína
EP2303266A4 (de) Pharmazeutische zusammensetzung mit einer 4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl-verbindung zur modulation der beta2-adrenorezeptor-aktivität
DK1816935T3 (da) System med kapsel, der har forseglingsmidler
BRPI0819093A2 (pt) compostos moduladores de sirtuína
DK2952177T3 (da) Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer
LT2959894T (lt) S1p receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui
BRPI0813304A2 (pt) Cabeça de furadeira.
DK3103448T3 (da) Farmaceutiske sammensætninger, der omfatter en S1P-modulator
ATE513831T1 (de) Pyridinä3,4-büpyrazinone
BRPI0811578A2 (pt) Tetramatos substituídos por 3-(2-alcóxi-fenila)
BRPI0914772A2 (pt) compostos heterocíclicos 1,2-dissubstituídos
DK3031825T3 (da) Immunbaserede aktivitetsassays for botulinum-toxin serotype a
DK1863787T3 (da) Hydrogeneret benzo[c]thiophenderivater som immunmodulatorer
ATE493411T1 (de) Pyrroloä2, 3-büpyridin-4-yl- benzolsulfonamidverbindungen als ikk2-hemmer
HUE071237T2 (hu) Fabry-kór kezelési lehetõségei
DK2291368T3 (da) Substitueret gamma-lactam som terapeutisk middel
BRPI0922597A2 (pt) "ftalazinona e análogos relacionados como moduladores de sirtuína".
BRPI0818348A2 (pt) Derivados de n-(pirazol-3-il)-benzamida como ativadores de glicocinase
DE602007010729D1 (de) Tampondruckanlage
BRPI0807961A2 (pt) agonista de alfa2c adrenorreceptor funcionalmente seletivos.
DK2041128T3 (da) Substituerede gamma-lactamer som terapeutiske agenser
DK2049480T3 (da) 2-arylindolderivater som mPGES-1-hæmmere
ATE515503T1 (de) Antiparasitische benzofuranmittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties